PHESGO Implementation Cuts Chair Time and Boosts Efficiency in HER2-Positive Breast Cancer Care
PHESGO reduced patient infusion time from 90 minutes to as little as 5, enhancing patient experience while maintaining efficacy and…
Donanemab-Azbt Demonstrated Long-Term Efficacy in Slowing Cognitive Decline
Donanemab-azbt shows sustained benefits in slowing cognitive decline in Alzheimer disease, emphasizing the value of early intervention and treatment.
Trastuzumab Biosimilar Demonstrates Sufficient Efficacy in HER2+ Advanced Gastric Cancer
Herzuma shows promising efficacy and safety as a cost-effective biosimilar for treating HER2+ advanced gastric cancer, offering new hope for…
Body Fat Percentage Outranks BMI as a Predictor of Long-Term Mortality
Research reveals body fat percentage and waist circumference are more accurate predictors of mortality risk than BMI, highlighting flaws in…
Discontinuing Lenalidomide After ASCT May Be Safe for Select MRD-Negative Patients With Multiple Myeloma
Discontinuing lenalidomide after 3 years of MRD negativity shows low relapse rates in multiple myeloma, offering hope for treatment-free remission.
Hepatitis D Reclassified as Carcinogenic, According to WHO
WHO reclassifies hepatitis D as carcinogenic, urging global action to combat viral hepatitis and reduce liver cancer risk.
Vaccine Coverage Among Kindergarteners Continues Decline in 2024 to 2025 School Year
Continuing a trend observed since the end of the COVID-19 pandemic, vaccine coverage among kindergarteners declined in the 2024 to…
Tirzepatide Provides Robust Cardiovascular Protection Versus Dulaglutide in T2D, ASCVD
In the SURPASS-CVOT clinical trial, tirzepatide was non-inferior to dulaglutide in a composite score of cardiovascular outcomes in patients with…